Please login to the form below

Not currently logged in
Email:
Password:

Rapidscan/GE Healthcare distribution deal

Rapidscan choses GE Healthcare to distribute coronary artery disease treatment in the UK and Germany

Rapidscan Pharma Solutions EU (RPS) has come to an agreement with GE Healthcare to promote and distribute Rapiscan (regadenoson) in the UK and Germany.

Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging in adult patients unable to undergo adequate exercise stress in the diagnosis of coronary artery disease (CAD).

Rapiscan is administered as a non-weight based bolus injection and is the first and only selective A2A adenosine receptor agonist to have a licence for use in this indication. 

Stephen Lightfoot, global MI-SPECT segment leader, Medical Diagnostics, GE Healthcare, said: "The opportunity to launch Rapiscan with Rapidscan Pharma Solutions EU leverages the expertise and unique capabilities of both organisations - to bring an important product used for the diagnosis of coronary artery disease to the UK and German marketplace."  

Regadenoson was launched in the US in 2008 following clinical trials of more than 2,000 patients with known or suspected CAD.

12th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics